New drug duo shows promise for rare blood cancer
NCT ID NCT04763616
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 2 study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with relapsed or refractory NK/T-cell lymphoma, a rare and aggressive blood cancer. The goal was to see if the combination could shrink tumors or stop the cancer from growing. Participants received the drugs for up to two years, and researchers measured how many achieved a complete response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- isatuximab and cemiplimab
- What this could lead to
- If successful, this combination could offer a new treatment option for people with hard-to-treat NK/T-cell lymphoma, potentially improving response rates.
- What could go wrong
- This is a small, early-phase study (37 participants) with no control group, so results may not be definitive. The drugs can cause significant side effects, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NK-CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Samsung Medical Center
Seoul, Kangnamgu, 06351, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized lymphoma therapy: could lower radiation be enough?
- Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
- Massive T-Cell lymphoma database aims to unlock new insights
- AI model aims to predict lymphoma treatment success
- New combo therapy aims to tame rare lymphoma without heavy side effects
- Supercharged donor cells take on lymphoma in early trial